Log In Sign up
The largest database of trusted experimental protocols

Hts ip plate

Manufactured by Merck Group
Visit Supplier
Sourced in United States

The HTS-IP plate is a laboratory equipment product designed for high-throughput screening (HTS) applications. It is a multi-well plate that provides a platform for conducting multiple experiments or assays simultaneously. The core function of the HTS-IP plate is to facilitate efficient and rapid screening of large numbers of samples or compounds, which is crucial in various research and development activities.

Automatically generated - may contain errors

Lab products found in correlation

Avidin horseradish peroxidase, by BD (6 mentions) Anti ifn γ antibody, by BD (3 mentions) Biotinylated anti ifnγ antibody, by BD (3 mentions) Easysep mouse cd8α positive selection kit, by STEMCELL (2 mentions) Anti mouse ifnγ antibody clone r4 6a2, by BD (1 mentions) Bdtmelispot set, by BD (1 mentions) Liberase tl, by Roche (1 mentions) Gentlemacs dissociator, by Miltenyi Biotec (1 mentions) C tube, by Miltenyi Biotec (1 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (1 mentions) Dnase 1, by Roche (1 mentions)

Close spelling variants of this product

MultiScreen HTS-IP filter plates (11 citations) Multiscreen HTS-IP plate (7 citations) HTS plates (2 citations) Multiscreen HTS IP 0.45-μm filter plates (2 citations) Multiscreen‐IP HTS plates (2 citations) PVDF MultiScreen HTS IP plates (2 citations)

8 protocols using hts ip plate

1

ELISPOT Analysis of Interferon-γ Release

Check if the same lab product or an alternative is used in the 5 most similar protocols
ELISPOT analysis was performed to detect interferon (IFN)-γ release from the lymphocytes that were collected from vaccinated mice. Specifically, 5 × 105 SPC, collected two weeks after the second electrovaccination of wt mice, were plated in duplicate into nitrocellulose 96-well HTS IP plates (Millipore, Bedford, MA, USA) that had been pre-coated with 5 μg/mL of purified anti-mouse IFNγ antibody (clone R4–6A2, BD Biosciences). SPC were stimulated for 48 h at 37 °C with 15 μg/mL of the predicted H2-Db immunodominant peptide (Pep2, FACENNDFL) (Twin Helix, Rho, MI) derived from both the m and hROS1 protein sequences. The selection of the peptide sequence was based on the online peptide prediction tool SYFPEITHI provided by the University of Tubingen (Tubingen, Germany). Briefly, both the murine and the human ROS1 sequences were analyzed according to the SYFPEITHI epitope prediction algorithm described in [77 (link)], in order to identify the predicted H2-Db-restricted nonamers. All possible nonamers were listed on the basis of their probability of being processed and presented to T cells, and among them, we selected the highest-scoring peptide shared by both sequences.
SPC stimulated with 2 μg/mL of Concanavalin A (ConA) were used as internal technical controls. Plates were developed according to the manufacturer’s instructions (BDTMELISPOT Set, BD Biosciences).
Riccardo F., Barutello G., Petito A., Tarone L., Conti L., Arigoni M., Musiu C., Izzo S., Volante M., Longo D.L., Merighi I.F., Papotti M., Cavallo F, & Quaglino E. (2020). Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. Vaccines, 8(2), 166.
+ Open protocol
+ Expand
2

Quantifying Antigen-Specific IFN-γ Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols
Splenocytes from vaccinated mice were plated at 1 × 106/well into 96-well HTS IP plates (Millipore) precoated with 5 μg/mL of rat anti-mouse IFN-γ (clone R4-6A2, BD Biosciences). Cells were then stimulated with 15 μg/mL of rat ErbB2 immunodominant peptide (TYVPANASL) peptide for 16 h in the incubator, or with concanavalin A (2 μg/ml) or medium alone as positive and negative controls, respectively. Images of the wells were acquired, and IFN-γ spots enumerated, with a microplate reader, along with a computer-assisted image analysis system (Immunospot; CTL Europe, Bonn, Germany), as previously described.82 (link)
Mina E., Wyart E., Sartori R., Angelino E., Zaggia I., Rausch V., Maldotti M., Pagani A., Hsu M.Y., Friziero A., Sperti C., Menga A., Graziani A., Hirsch E., Oliviero S., Sandri M., Conti L., Kautz L., Silvestri L, & Porporato P.E. (2023). FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy. Cell Reports Medicine, 4(12), 101306.
+ Open protocol
+ Expand
3

Tumor-specific CD8+ T Cell Functional Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
For tumor-specific CD8+ T cell functional assay in the MC38 model, 10 days after anti-CD47 Ab treatment, CD8+ T cells were purified from spleen. 2.5×105 CD8+ T cells were re-stimulated with MC38 cells at the ratio of 20:1 for 48 hours. 96-well HTS-IP plate (Millipore) was pre-coated with anti-IFN-γ antibody (BD Bioscience) with a 1:250 dilution overnight at 4° C. After co-culture, cells were removed. 2µg/ml biotinylated anti-IFN-γ antibody (BD Bioscience) with a 1:250 dilution was added and incubated for 2h at room temperature or overnight at 4°C. Avidin-horseradish peroxidase (BD Bioscience) with a 1:1000 dilution was then added and the plate was incubated for 1h at room temperature. The cytokine spots of IFN-γ were developed according to product protocol (BD Bioscience).
Xu M.M., Pu Y., Han D., Shi Y., Cao X., Liang H., Chen X., Li X.D., Deng L., Chen Z.J., Weichselbaum R.R, & Fu Y.X. (2017). Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein α signaling. Immunity, 47(2), 363-373.e5.
+ Open protocol
+ Expand
4

CD8+ T Cell IFN-γ ELISPOT Assay in B16-OVA Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
For antigen-specific CD8+ T cell functional assay in the B16-OVA model, 12 days after tumor inoculation, 3×105 lymphocytes were re-stimulated with 1μg/ml SIINFEKEL or MC38 tumor cells (lymphocyte:MC38 = 50:1) for 48 hours. 96-well HTS-IP plate (Millipore) was pre-coated with anti-IFNγ antibody (BD Bioscience) with a 1:250 dilution overnight at 4 °C. After co-culture, cells were removed. 2 mg/ml biotinylated anti-IFNγ antibody (BD Bioscience) with a 1:250 dilution was added and incubated for 2 h at room temperature or overnight at 4°C. Avidin-horseradish peroxidase (BD Bioscience) with a 1:1000 dilution was then added and the plate was incubated for 1h at room temperature. The cytokine spots of IFN-γ were developed according to product protocol (BD Bioscience).
Han D., Liu J., Chen C., Dong L., Liu Y., Chang R., Huang X., Liu Y., Wang J., Dougherty U., Bissonnette M., Shen B., Weichselbaum R., Xu M.M, & He C. (2019). Anti-tumor immunity controlled through mRNA m6A and YTHDF1 in dendritic cells. Nature, 566(7743), 270-274.
+ Open protocol
+ Expand
5

CD8+ T Cell IFN-γ ELISPOT Assay in B16-OVA Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
For antigen-specific CD8+ T cell functional assay in the B16-OVA model, 12 days after tumor inoculation, 3×105 lymphocytes were re-stimulated with 1μg/ml SIINFEKEL or MC38 tumor cells (lymphocyte:MC38 = 50:1) for 48 hours. 96-well HTS-IP plate (Millipore) was pre-coated with anti-IFNγ antibody (BD Bioscience) with a 1:250 dilution overnight at 4 °C. After co-culture, cells were removed. 2 mg/ml biotinylated anti-IFNγ antibody (BD Bioscience) with a 1:250 dilution was added and incubated for 2 h at room temperature or overnight at 4°C. Avidin-horseradish peroxidase (BD Bioscience) with a 1:1000 dilution was then added and the plate was incubated for 1h at room temperature. The cytokine spots of IFN-γ were developed according to product protocol (BD Bioscience).
Han D., Liu J., Chen C., Dong L., Liu Y., Chang R., Huang X., Liu Y., Wang J., Dougherty U., Bissonnette M., Shen B., Weichselbaum R., Xu M.M, & He C. (2019). Anti-tumor immunity controlled through mRNA m6A and YTHDF1 in dendritic cells. Nature, 566(7743), 270-274.
+ Open protocol
+ Expand
6

CD11c+ and CD8+ T Cell Functional Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
For bone-marrow CD11c+ cells functional assay, 2×104 purified CD11c+ or F4/80+ cells with were incubated with isolated CD8+ T cells from naive OT-I mice with EasySep™ Mouse CD8α Positive Selection Kit (STEMCELL) for three days at the ratio of 1:10. For tumor-specific CD8+ T cells functional assay in MC38-OTI model, 5 days after anti-CD47 mAb treatment, tumor DLNs were removed and CD8+ T cells were purified. 2×105 CD8+ T cells were incubated with BMDC at the ratio of 10:1 for 48 hours with/out 5µg/ml OTI peptide (SIINFEKL). For tumor-specific CD8+ T cells functional assay in MC38 and A20 models, 5 days after anti-CD47 Ab treatment, tumor DLNs were removed. DLN cells were re-stimulated with A20 or MC38. 96-well HTS-IP plate (Millipore) was pre-coated with anti-IFN-γ antibody (ebiosceince) with a 1:250 dilution overnight at 4 °C. After co-culture, cells were removed, 2 µg/ml biotinylated anti-IFN-γ antibody (ebiosceince) with a 1:250 dilution was added, and the plate was incubated for 2h at room temperature or overnight at 4 °C. Avidin-horseradish peroxidase (BD Pharmingen) with a 1:1000 dilution was then added and the plate was incubated for 1h at room temperature. The cytokine spots of IFN-γ were developed according to product protocol (Millipore).
Liu X., Pu Y., Cron K., Deng L., Kline J., Frazier W.A., Xu H., Peng H., Fu Y.X, & Xu M.M. (2015). CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors. Nature medicine, 21(10), 1209-1215.
+ Open protocol
+ Expand
7

CD11c+ and CD8+ T Cell Functional Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
For bone-marrow CD11c+ cells functional assay, 2×104 purified CD11c+ or F4/80+ cells with were incubated with isolated CD8+ T cells from naive OT-I mice with EasySep™ Mouse CD8α Positive Selection Kit (STEMCELL) for three days at the ratio of 1:10. For tumor-specific CD8+ T cells functional assay in MC38-OTI model, 5 days after anti-CD47 mAb treatment, tumor DLNs were removed and CD8+ T cells were purified. 2×105 CD8+ T cells were incubated with BMDC at the ratio of 10:1 for 48 hours with/out 5µg/ml OTI peptide (SIINFEKL). For tumor-specific CD8+ T cells functional assay in MC38 and A20 models, 5 days after anti-CD47 Ab treatment, tumor DLNs were removed. DLN cells were re-stimulated with A20 or MC38. 96-well HTS-IP plate (Millipore) was pre-coated with anti-IFN-γ antibody (ebiosceince) with a 1:250 dilution overnight at 4 °C. After co-culture, cells were removed, 2 µg/ml biotinylated anti-IFN-γ antibody (ebiosceince) with a 1:250 dilution was added, and the plate was incubated for 2h at room temperature or overnight at 4 °C. Avidin-horseradish peroxidase (BD Pharmingen) with a 1:1000 dilution was then added and the plate was incubated for 1h at room temperature. The cytokine spots of IFN-γ were developed according to product protocol (Millipore).
Liu X., Pu Y., Cron K., Deng L., Kline J., Frazier W.A., Xu H., Peng H., Fu Y.X, & Xu M.M. (2015). CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors. Nature medicine, 21(10), 1209-1215.
+ Open protocol
+ Expand
8

Antigen-specific CD8+ T cell assay for MC38 model

Check if the same lab product or an alternative is used in the 5 most similar protocols
For antigen-specific CD8 + T cell functional assay in the MC38 model, fourteen days after tumor inoculation, 5 3 10 5 lymphocytes were re-stimulated with 10 4 MC38 tumor cells (lymphocyte:MC38 = 50:1) for 72 hr. A 96-well HTS-IP plate (Millipore) was pre-coated with anti-IFNg antibody (BD) with a 1:250 dilution overnight at 4 C. After co-culture, cells were removed. Biotinylated anti-IFNg antibody (BioLegend) with a 1:250 dilution was added and incubated for 2 hr at room temperature. Avidin-horseradish peroxidase (BD) with a 1:1,000 dilution was then added and the plate was incubated for 1 hr at room temperature. IFNg spots were developed according to the manufacturer' s instructions (BD).
Orthotopic lung tumor model induction and tissue processing 4 3 10 5 LLC tumor cells were injected intravenously to WT and Mettl14 cKO mice. 12 days post tumor cells injection, WT and Mettl14 cKO mice were sacrificed and the lungs were collected. Samples were digested with 0.26 U/ml LiberaseTL (Roche) and 0.25 mg/ml DNaseI (Roche) in 1 ml of DMEM (GIBCO) in C-Tubes (Miltenyi) and briefly processed with a GentleMACS Dissociator (Miltenyi), followed by being incubated at 37 C for 30 min and processed a second time via GentleMACS. Single-cell suspension was then obtained by filtering the cells through a 70 mm cell strainer.
Dong L., Chen C., Zhang Y., Guo P., Wang Z., Li J., Liu Y., Liu J., Chang R., Li Y., Liang G., Lai W., Sun M., Dougherty U., Bissonnette M.B., Wang H., Shen L., Xu M.M, & Han D. (2021). The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer cell, 39(7).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!